The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
Open accessAbstract
Purpose: To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) –amplified advanced gastroesophageal adenocarcinoma. Patients and Methods: Patients with HER2-positive advanced gastroesophageal adenocarcinoma were randomly assigned at a one-to-one ratio to CapeOx plus lapatinib 1,250 mg or placebo daily. Primary end point was overall survival (OS) in patients with centrally confirmed HER2 amplification in the primary efficacy population. Results: A total of 545 patients were randomly assigned, and 487 patients comprised the primary efficacy population. Median OS in the lapatinib and placebo arms was 12.2 (95% CI, 10.6 to 14.2) and 10.5 months (95% CI, 9.0 to 11.3), respectively, which was not significantly different (hazard ratio, 0.91; 95% CI, 0.73 to 1.12). Median progression-free survival in the lapatinib and placebo arms was 6.0 (95% CI, 5.6 to 7.0) and 5.4 months (95% CI, 4.4 to 5.7), respectively (hazard ratio, 0.82; 95% CI, 0.68 to 1.00; P = .0381). Response rate was significantly higher in the lapatinib arm: 53% (95% CI, 46.4 to 58.8) compared with 39% (95% CI, 32.9 to 45.3) in the placebo arm (P = .0031). Preplanned exploratory subgroup analyses showed OS in the lapatinib arm was prolonged in Asian and younger patients. No correlation was observed between HER2 immunohistochemistry status and survival. There were increased toxicities in the lapatinib arm, particularly diarrhea. Conclusion: Addition of lapatinib to CapeOx did not increase OS in patients with HER2-amplified gastroesophageal adenocarcinoma. There were clear differences in the effect of lapatinib depending on region and age. Future studies could examine this correlation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“0 Range 19-86 27-84 Male sex 189 (76) 176 (74) HER2 IHC status 0 13 (5) 14 (6) 1+ 34 (14) 20 (8) 2+ 58 (23) 50 (21) 3+ 143 (57) 154 (65) Unknown 1 (, 1) 0 ECOG performance status 0 79 (32) 63 (26) 1 149 (60) 153 (64) 2 21 (8) 22 (9) Pylorus intact Yes 193 (78) 180 (76) No 56 (22) 58 (24) Prior adjuvant or neoadjuvant…”
Self-citationBang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Self-citationComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Celli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., Buist, A. S., Calverley, P. M. A., Chavannes, N., Dillard, T., Fahy, B., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,421
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Deng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624
Self-citationTan, I. B., Ivanova, T., Lim, K. H., Ong, C. W., Deng, N., Lee, J., Tan, S. H., Wu, J., Lee, M. H., Ooi, C. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.042 · Cited by 357
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
Wainberg, Z. A., Anghel, A., Desai, A. J., Ayala, R., Luo, T., Safran, B., Fejzo, M. S., Hecht, J. R., Slamon, D. J., & Finn, R. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1112 · Cited by 211
Self-citationPress, M. F., Finn, R. S., Cameron, D., Di Leo, A., Geyer, C. E., Villalobos, I. E., Santiago, A., Guzman, R., Gasparyan, A., Ma, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1056 · Cited by 171
Self-citationCapecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Okines, A. F. C., & Ashley, S. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0911925 · Cited by 164
Iqbal, S., Goldman, B., Fenoglio-Preiser, C. M., Lenz, H. J., Zhang, W., Danenberg, K. D., Shibata, S. I., & Blanke, C. D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr021 · Cited by 158
Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients
Koch, K. M., Reddy, N. J., Cohen, R. B., Lewis, N. L., Whitehead, B. P., Mackay, K., Stead, A. G., Beelen, A. P., & Lewis, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3285 · Cited by 147
Gelmon, K. A., Boyle, F. M., Kaufman, B., Huntsman, D. D., Manikhas, A., Leo, A. D., Martín, M., Schwartzberg, L. S., Dent, S. F., Ellard, S. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.lba671 · Cited by 68
A new class of bronchodilator improves lung function in COPD: a trial with GSK961081
Wielders, P. L. M. L., Ludwig-Sengpiel, A., Locantore, N., Baggen, S. F., Chan, R. H., & Riley, J. (2013) · European Respiratory Journal · doi:10.1183/09031936.00165712 · Cited by 55
Cited by
Current treatment and recent progress in gastric cancer
Joshi, S. S., & Badgwell, B. D. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21657 · Cited by 1,677
Machlowska, J., Baj, J., Sitarz, M., Maciejewski, R., & Sitarz, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114012 · Cited by 1,520
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Self-citationHER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Self-citationGastric cancer treatment: recent progress and future perspectives
Guan, W.-L., He, Y., & Xu, R.-H. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01451-3 · Cited by 944
Metadata
- Authors
- Hecht, J. R., Bang, Y.-J., Qin, S. K., Chung, H. C., Xu, J. M., Park, J. O., Jeziorski, K., Shparyk, Y., Hoff, P. M., Sobrero, A., Salman, P., Li, J., Protsenko, S. A., Wainberg, Z. A., Buyse, M., Afenjar, K., Houé, V., Garcia, A., Kaneko, T., Huang, Y., Khan-Wasti, S., Santillana, S., Press, M. F., & Slamon, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-02-10
- Volume
- 34
- Issue
- 5
- Pages
- 443-451
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2185378752
- Cited by
- 624
- References
- 22
- FWCI
- 47.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.